TME Pharma N.V. announced a clinical update on survival of first-line glioblastoma patients in the GLORIA expansion arm evaluating NOX-A12, the CXCL12 inhibitor, in combination with standard of care radiotherapy and anti-VEGF, bevacizumab. With a median follow-up to date of 10 months in this arm of the trial median overall survival (mOS) has not yet been reached, and five of six patients (83%) remain alive. The 10-month timepoint is an important landmark for assessment since this is the expected survival for patients with MGMT unmethylated tumors and incomplete resection.
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
0.244 EUR | -1.81% | -2.98% | +6.09% |
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+6.09% | 7.57M | |
+1.12% | 42.59B | |
+6.77% | 40.65B | |
+47.98% | 40.57B | |
-11.96% | 26.77B | |
+6.01% | 24.81B | |
-24.92% | 18.17B | |
+27.16% | 12.05B | |
-3.63% | 11.7B | |
+7.30% | 11.1B |
- Stock Market
- Equities
- ALTME Stock
- News TME Pharma N.V.
- Tme Pharma Provides Clinical Update on the Gloria Expansion Arm Testing Nox-A12 in Combination with Radiotherapy and Bevacizumab in Patients with Glioblastoma